Nr 4 2024 – Hjärta & Kärl

1.Kelly et al 2010. Pediatr Diabetes; 11:552-555.

3. Block G et al. 1992. Fruit, vegetables and cancer prevention: A review of the epidemiological evidence. Nutr Cancer: 18(1):1-29.
4. Nylander M (2015) Riktigt Näringsintag & God Munhygien är grundläggande för bästa hälsa. Romi Tryck, Produktion T&M Media. Sid 3-58.
5. Nylander M (2014) Bakterier i munnen kan göra dig hjärtsjuk. Medicinsk Access 4/5:27-29.
6. Nylander M & Carlmark B (2009) Vad är oxidativ stress. Näringsmedicinsk tidskrift 3:9-10, 21-22.
7. Nylander M (2011) Oxidativ stress. STARK 3:35-38.
8. Nylander M (2015) Avancerat kosttillskott kan minska ohälsosam oxidativ stress. Medicinsk Access 2:6-11.
9. Esselstyn CB et al. 1995. A strategy to arrest and reverse coronary artery disease: a 5-year longitudinal study of a single phisician’s practice. J. Family Practice 41: 560-568.
10. Esselstyn CB 1998. Introduction: More than coronary heart disease. Am J Cardiol; 82: 5-9.

12?

13. Benton D. & Roberts G. 1988. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet; 1 (8578): 140-143.
14. Benton D et al . 1991. Vitamin and mineral supplements imrove the intelligence scores and concentration of six-year-old children. Personality and individual differences; 12(11): 1151-1158.
15. Schoenthaler S. et al. 1991. Controlled trial of vitamin-mineral supplementation on intelligence and brain function. Personality and individual differences; 12(4): 343-350.
16. Yudkin J. 1991. Intelligence of children and vitamin-mineral supplements: the DFR study. Discussion, conclusion and consequences. Personality and individual differences; 12 (4): 363-365.

1.Teicholz  N. A short history of saturated fat: the making and unmaking of a scientific consensus. Current opinion on Endocrinology Diabetes and Obesity. 2023:30(1)

2. Astrup. A., Magkos.F., Bier D.M. et al. Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020:76;7
3. Antoni R. Dietary saturated fat and cholesterol: cracking the myths around eggs and cardiovascular disease. Journal of Nutritional Science. 2023: 12
4. Brassard D., Tessier-Grenier M., Allaire J., et al. Comparison of the impact of SFAs from cheese and butter on cardiometabolic risk factors: a randomized controlled trial. The American Journal of Clinical Nutrition. 2017:105;4.
5. Zinöcker M.K., Svendsen K., Nitter Dankel S. The homeoviscous adaptation to dietary lipids (HADL) model explains controversies over saturated fat, cholesterol, and cardiovascular disease risk. American Journal of Clinical Nutrition. 2021:113;2

1. Rice-Evans C et al 1992. Free radicals, lipoproteins and cardiovascular dysfunction. Molecular Aspects of Medicine; Vol 13: 1-111. Pergamon Press.
2. Berliner JA et al. Minimally modified low density lipoprotein stimulates monocyte endothial interactions. J. Clin. Invest. 85, 1260-1266, 1990.
3. Regnström J et al. 1992. Succeptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet; 339: 11833-36.
4. Sachdeva et al. 2009. Am Heart J; 157:111-117.
5. Johnston et al. 2006. Am J Cardiology; 97: 640-645.
6. Holvoet et al. 2008. JAMA; 299: 2287-2293.
7. Kelly et al 2010. Pediatr Diabetes; 11:552-555.
8. Garelnabi MO et al.2008. Evaluation of a novel colorimetric assay for free oxygen radicals as marker of oxidative stress. Clinical Biochemistry; 41: 1250-1254.
9. Nylander M. 2017. Processade tomatprodukter ger betydande skyddande effekter mot utveckling av ateroskleros. Medicinsk Access;1:19-25.
10. Carmeli E et al 2008. Effects of Endogenous Antioxidant glabridin on Oxidized LDL. J. of Basic & Clinical Physiology & Pharmacology. Vol 19. No 1.
11. Block G et al. 1992. Fruit, vegetables and cancer prevention: A review of the epidemiological evidence. Nutr Cancer: 18(1):1-29.
12. Nylander M (2015) Riktigt Näringsintag & God Munhygien är grundläggande för bästa hälsa. Romi Tryck, Produktion T&M Media. Sid 3-58.
13. Cambell TC & Cambell TM. 2006. The china study. ISBN 978-91-979926-5-7.
14. Parthasarathy S et al. 1990. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA;87: 3894-3898.
15. Crane FL et al. 1993. The essential functions of coenzyme Q. Clin Investig; 71: 55-59
16. Nylander M et al 1995. Plasma levels of coenzyme Q10 before and after oral supplementation: a bioavailability study. CoQ Res Biol Med; 3 (1): 25-32.
17. Mohr D et al. 1992. Dietary supplementation with Coenzyme Q₁₀ results in increased levels of ubiquinol10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochem. Biophys Acta;1126: 247-254.
18. Folkers K et al. 1990. Lovastatin decreases coenzyme Q10 levels in humans. Proc Natl Acad Sci USA; 87:8931-8934.
19. Disilvestro RA et al. 2013. Lycopene concentrate supplementation decreases plasma values for C-reactive protein and oxidized LDL. The FASEB Journal;27: 638.13
20. Young K et al. 2011. Effects of lycopene supplemetation on oxidative stress and markers of endothial function in healthy men. Atherosclerosis; 215: 189-195.
21. Silaste et al. 2007. Tomato juice decreases LDL cholesterol levels and increases LDL resistance to oxidation. Brittish J of Nutrition; 98: 1251-1258.
22. McEneny et al. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. J of Nutritional Biochemistry. Available online at www.sciencedirect.com
23. Visioli F et al. 2003. Protective activity of tomato products on in vivo markers of lipid peroxidation. Eur J Nutr; 42: 201-206.
24. Agarwal S & Venketeshwer Rao A. 1998. Tomato lycopene and low density lipoprotein oxidation: A human dietary intervention study. Lipids; 33 (10).
25. Burton.Freeman B et al. 2012. Protective activity of processed tomato products on postrandial oxidation and inflammation: A clinical trial in healthy weight men and women. Mol Nutr Food Res; 00: 1-10.
26. Upritchard JE et al. 2000. Effect of supplementation with tomato juice, vitamin E and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes.

Diabets Care; 23: 733-738

[1]. WHO: The top 10 causes of death. Hämtad 2024-01-25 The top 10 causes of death (who.int)

2. 2. Hjärt-lungfonden. Hämtad 2024-01-25 Livsviktig forskning pågår | Hjärt-Lungfonden (hjart-lungfonden.se)

3.Socialstyrelsen. Statistik om läkemedel 2022. Hämtad 2024-01-25 Statistik om läkemedel – Socialstyrelsen

4. 4. Jenny Loftrup. Så tar du hand om ditt hjärta. Vetenskap och Hälsa, maj 2023. Så tar du hand om ditt hjärta – Vetenskap och Hälsa (vetenskaphalsa.se)
5. 5. Cirilli I et al. Role of Coenzyme Q10 in Health and Disease: An Update on the Last 10 Years (2010-2020). Antioxidants (Basel). 2021 Aug 23;10(8):1325. Role of Coenzyme Q10 in Health and Disease: An Update on the Last 10 Years (2010–2020) – PMC (nih.gov)
6. 6. Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007 Jun;7 Suppl:S78-88. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations – PubMed (nih.gov)
7. 7. Lee BJ et al. A significant correlation between the plasma levels of coenzyme Q10 and vitamin B-6 and a reduced risk of coronary artery disease. Nutr. Res. 2012, 32, 751–756. A significant correlation between the plasma levels of coenzyme Q10 and vitamin B-6 and a reduced risk of coronary artery disease – PubMed (nih.gov)
8. 8. Banach M et al. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations–A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015 Sep;99:329-36. Statin therapy and plasma coenzyme Q10 concentrations–A systematic review and meta-analysis of placebo-controlled trials – PubMed (nih.gov)

9.Kalén A et al. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989 Jul;24(7):579-84. Age-related changes in the lipid compositions of rat and human tissues – PubMed (nih.gov)

10. 10. Alehagen U et al. Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens. PLoS ONE 2015, 10, e0141641. Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens – PMC (nih.gov)
11. Williams B et al. J Hypertens. 2018 Oct;36(10):1953-2041. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension – PubMed (nih.gov)

12. 12. Sabbatinelli J et al. Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial. Nutrients. 2020 Apr 15;12(4):1098. Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial – PubMed (nih.gov)

13, Thijssen DHJ et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur. Heart J. 2019, 40, 2534–2547. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans – PubMed (nih.gov)

14.Mortensen SA et al. Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial. JACC Heart Fail. 2014, 2, 641–649. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial – PubMed (nih.gov)

15. 1 Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors. 2008;32(1-4):119-28. Supplemental ubiquinol in patients with advanced congestive heart failure – PubMed (nih.gov)

16.Hosoe K et al. Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol. 2007 Feb;47(1):19-28. Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers – PubMed (nih.gov)

17.Ikematsu H et al. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol. 2006 Apr;44(3):212-8. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial – PubMed (nih.gov)

18.Zhang Y et al. Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men. Food Funct. 2018 Nov 14;9(11):5653-5659. Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men – PubMed (nih.gov)

19.García-Corzo L et al. Ubiquinol-10 ameliorates mitochondrial encephalopathy associated with CoQ deficiency. Biochim Biophys Acta. 2014 Jul;1842(7):893-901. Ubiquinol-10 ameliorates mitochondrial encephalopathy associated with CoQ deficiency – PubMed (nih.gov)

1.Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A, Biolo G. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721.

2.Lippi G, Guidi G. Lipoprotein(a): from ancestral benefit to modern pathogen? QJM. 2000 Feb;93(2):75-84.

3.Kostakou PM, Hatzigeorgiou G, Kolovou V, Mavrogeni S, Kolovou GD. Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels. Curr Med Chem. 2017;24(10):969-978.

4.Koutsogianni AD, Liamis G, Liberopoulos E, Adamidis PS, Florentin M. Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications. Pharmaceuticals (Basel). 2023 May 16;16(5):750.

5.Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017 Feb 14;69(6):692-711.

6.Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, Blaha MJ, Andrica F, Martin SS, Borza C, Lip GY, Ray KK, Rysz J, Hazen SL, Banach M. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016 Jan 12;6:19188.

7.Sahebkar A, Simental-Mendía LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016 Mar;105:198-209.

8.Kosmas CE, Bousvarou MD, Papakonstantinou EJ, Tsamoulis D, Koulopoulos A, Echavarria Uceta R, Guzman E, Rallidis LS. Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a). Int J Mol Sci. 2023 Sep 3;24(17):13622.

9.Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008 Jul 8;52(2):124-31.

10.Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A, Biolo G. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721.

11.Di Fusco SA, Maggioni AP, Scicchitano P, Zuin M, D’Elia E, Colivicchi F. Lipoprotein (a), Inflammation, and Atherosclerosis. J Clin Med. 2023 Mar 27;12(7):2529

Nattokinas: Ett naturligt skydd mot åderförkalkning

1. Nagata C et al. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. Am J Clin Nutr. (2017) 105:426-31.
2. Sumo H et al. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese natto; a typical and popular soybean f in the Japanese diet. Experentia. (1987) 43: 1110-1.

3. Suzuki Y et al. Dietary supplementation with fermented soybeans supresses intimal thickening. Nutrition. (2003) 19: 261-4.
4. Suzuki Y et al. Dietary supplementation with fermented soybean, natto, suppresses intimal thickening and modulate the lysis of mural trombi after endothelial injury in rat femoral artery. Life Sci (2003) 73: 1289-98.
5. Kang SJ et al. Korean red ginseng combined with nattokinase amelioriates dyslipidemia and the area of aortic plaquesin high cholesterol-diet fed rabbits. Food Sci Biotechnol. (2014) 23: 283-7.
6. Xie S et al. Preparation of nattokinase and study on its hypolipidemic effect. Chin J Biochem Pharm. Food Sci. (2015) 35: 17-20.
7. Meng F et al. Effects of nattokinase on blood lipid and rheology in atherosclerosis model rat. Chin J Lab Diagn. (2013) 17:1567-9.
8. Duan Z et al. Study on the antioxidative activity and effects on experimental hyperlipidemia of natto extract. Acta Nutrimenta Sin. (2004) 26: 296-9.
9. Park KJ et al. The antithrombotic and fibrinolytic effect of natto in hypercholesterolemia rats. Prev. Nutr. Food Sci. (2012) 17: 78-82.
10. Iwai K et al. Antioxidative functions of natto, a kind of fermented soybeans: effect on LDL oxidation and lipid metabolism in cholesterol-fed rats. J Agric Food Chem. (2002) 50: 3597-601.
11. Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized trial. Clin Hemorheol Microcirc. (2021) 78: 339-53.
12. Ren N et al. A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Nat Med J China. (2017) 97: 2038-42.
13. Chen H et al. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Front Cardiovasc Med (2022) 9: 964977.
14. Chen H et al. Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights. (2018) 13:1177.
15. Union E. Commision implementing Decision (EU) 2017/115 of 20 January 2017 Authorising the placing on the market of Fermented Soybean extract as a Novel Food Ingredient under regulation (EC) 258/97 of the European Parliament and of the Council notified under document C (2017) 165. In :Union TE, editor. Brussels. (2017).
16. Lampe BJ & English JC. Toxicological assessment of nattokinase derived from Bacillus subtilis in natto. Food Chem Toxicol. (2016) 88:87-99.

1.Morelli M.B., Gambardella J., Castellanos V., et.al. Vitamin C and Cardiovascular Disease: An Update. Antioxidants (Basel). 2020:9;12

2.May J.M., Harrison F.E. Role of Vitamin C in the function of the vascular endothelium. Antioxid Redox Signal. 2013:19(17)

3.Kugiyama K., Motoyama T., Hirashima O., et. al. Vitamin C attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol. 1998:32

4.Jeserich M, Schindler T, Olschewski M, et.al. Vitamin C improves endothelial function of epicardial coronary arteries in patients with hypercholesterolaemia or essential hypertension-assessed by cold pressor testing. Eur Heart J. 1999:20;22

5.Schindler T.H., Magosaki N., Jeserich M., et.al. Effect of ascorbic acid on endothelial dysfunction of epicardial coronary arteries in chronic smokers assessed by cold pressor testing. Cardiology. 2001;94;4

6.Tousoulis D., Xenakis C., Tentolouris C., et.al. Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina. Heart. 2005;91;10

7.Solzbach U., Hornig B., Jeserich M., Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation. 1997;96;5

8.Brabson JP, Leesang T, Mohammad S, Cimmino L. Epigenetic regulation of genomic stability by vitamin C. Front Genet. 2021;12:675780. https://doi.org/10.3389/fgene.2021.675780.

9.Hemilä H. de Man A.M.E. Vitamin C deficiency can lead to pulmonary hypertension: a systematic review of case reports. BMC Pulmonary Medicine. 2024: 24;140

10.Chen L., Sun X., Wang Z., et.al. The impact of plasma vitamin C levels on the risk of cardiovascular diseases and Alzheimer’s disease: a mendelian randomization study. Clin Nutr. 2021;40;10

11.Lynch S.M., Gaziano J.M., Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. Subcell Biochem. 1996:25 10.1007/978-1-4613-0325-1_17

12.Ruiz-León A.M., Lapuente M., Estruch R., Casas R. Clinical Advances in Immunonutrition and Atherosclerosis: A Review. Nutritional Immunology. 2019:10

13.McRae M.P. Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. Journal of Chiropractic Medicine. 2008:7;2

14.Pfister R., Sharp S.J., Luben R., et.al. Plasma vitamin C predicts incident heart failure in men and women in European Prospective Investigation into Cancer and Nutrition-Norfolk prospective study. Am Heart J. 2011;162;2

15.Wannamethee S.G., Bruckdorfer K.R., Shaper A.G., et.al. Plasma vitamin C, but not vitamin E, is associated with reduced risk of heart failure in older men. Circ Heart Fail. 2013;6;4

16.Jia J., Zhang J., He Q., et.al. Association between dietary vitamin C and abdominal aortic calcification among the US adults. Nutrition Journal. 2023:22

17.Juraschek S.P., Guallar E., Appel L.J., Miller E.R. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;95;5

18.Ashor A.W., Lara J., Mathers J.C., Siervo M. Effect of vitamin C on endothelial function in health and disease: a systematic review and meta-analysis of randomised controlled trials. Atherosclerosis. 2012;235

1. Nagata C, Nakamura K, Wada K et al. Association of dietary fat, vegetables and antioxidant micronutrients with skin ageing in Japanese women. British Medical Journal. 2010;103:
2. de Spirt S, Stahl W, Tronnier H, Sies H et al. Intervention with flaxseed and borage oil supplements modulates skin condition in women. British Journal of Nutrition. 2009;101
3. American Academy of Dermatology Association. Heart disease: 12 warning signs that appear on your skin (aad.org)

4. Hirschmann JV and Raugi GJ. “Blue (or purple) toe syndrome.” J Am Acad Dermatol. 2009; 60(1):1-20.

1.Goda bakterier: Hellre mångfald än enfald, Fredrik Hedlund, först publicerat i tidningen Medicinsk Vetenskap nr 3/2017. Hämtad 2024-11-05  Goda bakterier: Hellre mångfald än enfald | Karolinska Institutet

2. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun 13;486(7402):207-14.
3. Bourdeau-Julien I, Castonguay-Paradis S, Rochefort G, Perron J, Lamarche B, Flamand N, Di Marzo V, Veilleux A, Raymond F. The diet rapidly and differentially affects the gut microbiota and host lipid mediators in a healthy population. Microbiome. 2023 Feb 11;11(1):26.
4. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484.
5. Larsen N., Vogensen F.K., van den Berg F.W.J., Nielsen D.S., Andreasen A.S., Pedersen B.K. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5:e9085.
6. Ott S.J., Musfeldt M., Wenderoth D.F., Hampe J., Brant O., Fölsch U.R. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685–693.
7. Wilkins LJ, Monga M, Miller AW. Defining Dysbiosis for a Cluster of Chronic Diseases. Sci Rep. 2019 Sep 9;9(1):12918.
8. Neuman H, Forsythe P, Uzan A, Avni O, Koren O. Antibiotics in early life: dysbiosis and the damage done. FEMS Microbiol Rev. 2018 Jul 1;42(4):489-499.

9.Heiman ML, Greenway FL. A healthy gastrointestinal microbiome is dependent on dietary diversity. Mol Metab. 2016 Mar 5;5(5):317-320.

10.Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016 Jan 14;529(7585):212-5.

11. Wastyk HC, Fragiadakis GK, Perelman D, Dahan D, Merrill BD, Yu FB, Topf M, Gonzalez CG, Van Treuren W, Han S, Robinson JL, Elias JE, Sonnenburg ED, Gardner CD, Sonnenburg JL. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021 Aug 5;184(16):4137-4153.
12. Rezac S, Kok CR, Heermann M, Hutkins R. 2018. Fermented foods as a dietary source of live organisms. Front Microbiol 9:1785.
13. Marco ML, Heeney D, Binda S, Cifelli CJ, Cotter PD, Foligné B, Gänzle M, Kort R, Pasin G, Pihlanto A, Smid EJ, Hutkins R. 2017. Health benefits of fermented foods: microbiota and beyond. Curr Opin Biotechnol 44:94–102.
14. Kang DW, Adams JB, Coleman DM, Pollard EL, Maldonado J, McDonough-Means S, Caporaso JG, Krajmalnik-Brown R. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep. 2019 Apr 9;9(1):5821.

Arcangeli P.

1.Pycnogenol in chronic venous insufficiency. Fitoterapia. 2000 Jun;71(3):236-44.

“Effects of Pycnogenol on post-thrombotic syndrome and recurrent thrombosis: A six-year study in at-risk patients”

Minerva Cardioangiologica, 2023

2. ”Prevention of recurrent venous thrombosis and post-thrombotic syndrome”

Minerva Cardioangiol. (2018) Jun;66(3), 238-245

3. Pourmasoumi M, Hadi A, Mohammadi H, Rouhani MH. Effect of pycnogenol supplementation on blood pressure: A systematic review and meta-analysis of clinical trials. Phytother Res. 2020 Jan;34(1):67-76.